{"name":"Cassava Sciences","slug":"cassava","ticker":"SAVA","exchange":"NASDAQ","domain":"cassavasciences.com","description":"Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.","hq":"Austin, TX","founded":0,"employees":"","ceo":"Remi Barbier","sector":"Neuroscience / Clinical-Stage Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$950M","metrics":{"revenue":41119000,"revenueGrowth":0,"grossMargin":0,"rdSpend":26590000,"netIncome":-90973000,"cash":118355000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Cassava Sciences Announces FDA Clearance of IND for Simufilam","summary":"Cassava Sciences announced that the FDA has cleared the Investigational New Drug (IND) application for simufilam, allowing the company to proceed with clinical trials.","drugName":"simufilam","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Cassava Sciences Reports Third Quarter 2023 Financial Results","summary":"Cassava Sciences reported its financial results for the third quarter of 2023, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Cassava Sciences Announces Collaboration with University of California, San Diego","summary":"Cassava Sciences announced a collaboration with the University of California, San Diego to develop new treatments for neurodegenerative diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQUHpBSGFiQ2ZMUk1YY0RKU1Q0UXpHWE5uS0FoX3ctaW5oOEFxQWZGQS14QzFDTDdEYWlLNk9jSG1GS3pqX2Q2c2dRSnVaNW9GWm1iSXVJTjFVTFVqbWNSUU05VTJuY0NJT0VlcTJNcEJsWWJPNWhiSWxRblZoS2V5OGZCZjdfenZLVzRYNzJsdWVqckIzc05fRGwxUXh5elRFc1pDdGFrem93WUUyTWxyc0xNNk9FVXptTzl5Q3E5elpJTUF3VTdGZ2NCVDdwYmlMOVZCQ1o1Vl9MaUxaZF9WdHM2aGI3Zw?oc=5","date":"2026-03-12","type":"earnings","source":"GlobeNewswire","summary":"Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire","headline":"Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AJBVV95cUxNdll6WXhMdDY4aktkYkdtcWU3cXZHWU5zQXBfaHNxTmVLb2RwT2JrSkV4bDlfTEp2VkltX3V6bHJHTjVNNGtfQS1TRmpqbzVtT1hjakFjZnV2TllIWm5UdG5GTXAtbzE3VFhZZ2w1NS1RU2Y2RGZ2RnQyYnMxVHBpaTVvdlFhbE9KeUVsYm8wNVoyS19ZdzQ5NEtvOTRxdTRrZ205TU12NUhsUXdpbHRLckNUMUJwbXNieEwtY0pybFdOeFJSTFBwaS1uNXlyUmVZWHRSczRPa3R3VUZ0WWVsNE1DcHBwcEpaRUt5LUlZdlZvRmVGUXNlelM2SE10RkMtdTdkTmpBcjlEV01rUG5NdUt2YS1Oc3R4LXVabEhRYzgzaklKVjc3U3BwZmxUVlVjTXhGUHZnY1AtVmFjd0h3S19OSjhlRGcxRmdpZUZkb2VMS3dzZm8taQ?oc=5","date":"2026-03-11","type":"pipeline","source":"MSN","summary":"Cassava Sciences taps Joseph Hulihan as chief medical officer - MSN","headline":"Cassava Sciences taps Joseph Hulihan as chief medical officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQekJ4X19qdHJsdHJuVjFDcmttTHlCNmFOZnlOVmVCYjhzSl9lbjNUQjNyVnVmeDFPTFQ4WnlBSkQyWU93dkNsdTFxcWt0elMxV3lKaDMtN0pldmhnVlhnQmlvejRnMWR4ZmduaUF1WjdnUlg1ZVJGWkw3YldTTFljVnBWc19MVGZjNXRVMw?oc=5","date":"2026-03-10","type":"pipeline","source":"Yahoo Finance","summary":"Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. - Yahoo Finance","headline":"Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNTTNHZ3FjZWtIZUVqbXp5VXRRZTU5STNmbDRaYnlELWNza21ESTExeWx4Qml0aFdHZHk4RGQxdmdsaWVFLURKenN5bllHRXBVNWUtQ0NWT2d5OV9YWHBfSTZ6XzBWT0RodDJucmI4Ykp2ZmtzVGJyUFVJbFFQVmxyNVl2ekhlNUhZUENWNmFQX0Z1cHdXeEpGTGxPUFNqdVRtcmw3Y2R2UUN0Tmt0NEE?oc=5","date":"2026-02-19","type":"pipeline","source":"reuters.com","summary":"Cassava Sciences says US DOJ has closed investigation into company - reuters.com","headline":"Cassava Sciences says US DOJ has closed investigation into company","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Eli Lilly","Roche"],"therapeuticFocus":["Alzheimer's disease","neurodegenerative diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":41119000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":41119000,"period":"2013-12-31"},{"value":41119000,"period":"2013-12-31"},{"value":41119000,"period":"2013-12-31"},{"value":35244000,"period":"2013-12-31"},{"value":35244000,"period":"2013-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":26590000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-90973000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":118355000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}